111 related articles for article (PubMed ID: 22593440)
21. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer.
Park IJ; Choi GS; Jun SH
Anticancer Res; 2009 Oct; 29(10):4303-8. PubMed ID: 19846991
[TBL] [Abstract][Full Text] [Related]
22. Elevated plasma gastrin, CEA, and CA 19-9 levels decrease after colorectal cancer resection.
Bombski G; Gasiorowska A; Orszulak-Michalak D; Neneman B; Kotynia J; Strzelczyk J; Janiak A; Malecka-Panas E
Int J Colorectal Dis; 2003 Mar; 18(2):148-52. PubMed ID: 12548418
[TBL] [Abstract][Full Text] [Related]
23. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
[TBL] [Abstract][Full Text] [Related]
24. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG PET-CT in evaluation of postoperative colorectal cancer patients with rising CEA level.
Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh B; Kapoor R; Gupta R
Nucl Med Commun; 2011 Sep; 32(9):789-93. PubMed ID: 21760561
[TBL] [Abstract][Full Text] [Related]
26. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the RUNX3 gene methylation in serum DNA from esophagus squamous cell carcinoma, gastric and colorectal adenocarcinoma patients.
Zheng Y; Zhang Y; Huang X; Chen L
Hepatogastroenterology; 2011; 58(112):2007-11. PubMed ID: 22234069
[TBL] [Abstract][Full Text] [Related]
28. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].
Grotowski M; Maruszyński M; Piechota W
Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841
[TBL] [Abstract][Full Text] [Related]
29. Utility of serum preoperative carcinoemberyonic antigen in colorectal cancer patients.
El-Awady S; Lithy R; Morshed M; Khafagy W; Abd Monem H; Waleed O; Badr S; Fekry A; El Nakeeb A; Ghazy H; El Yamany M; Metwally T; El-Arman M; Farid M
Hepatogastroenterology; 2009; 56(90):361-6. PubMed ID: 19579599
[TBL] [Abstract][Full Text] [Related]
30. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
31. High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform.
Lilleberg SL; Durocher J; Sanders C; Walters K; Culver K
Ann N Y Acad Sci; 2004 Jun; 1022():250-6. PubMed ID: 15251969
[TBL] [Abstract][Full Text] [Related]
32. Tumor markers in patients with relapse of colorectal carcinoma.
Lipská L; Visokai V; Levý M; Svobodová S; Kormunda S; Fínek J
Anticancer Res; 2007; 27(4A):1901-5. PubMed ID: 17649792
[TBL] [Abstract][Full Text] [Related]
33. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
[TBL] [Abstract][Full Text] [Related]
34. Carcinoembryonic antigen messenger RNA expression using nested reverse transcription-PCR in the peripheral blood during follow-up period of patients who underwent curative surgery for biliary-pancreatic cancer: longitudinal analyses.
Mataki Y; Takao S; Maemura K; Mori S; Shinchi H; Natsugoe S; Aikou T
Clin Cancer Res; 2004 Jun; 10(11):3807-14. PubMed ID: 15173089
[TBL] [Abstract][Full Text] [Related]
35. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063
[TBL] [Abstract][Full Text] [Related]
36. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer.
Chau I; Allen MJ; Cunningham D; Norman AR; Brown G; Ford HE; Tebbutt N; Tait D; Hill M; Ross PJ; Oates J
J Clin Oncol; 2004 Apr; 22(8):1420-9. PubMed ID: 15007086
[TBL] [Abstract][Full Text] [Related]
37. Value of serum carbohydrate antigen 19-9 for predicting extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma.
Sasaki A; Kawano K; Inomata M; Shibata K; Matsumoto T; Kitano S
Hepatogastroenterology; 2005; 52(66):1814-9. PubMed ID: 16334783
[TBL] [Abstract][Full Text] [Related]
38. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
39. Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool.
Frattini M; Gallino G; Signoroni S; Balestra D; Battaglia L; Sozzi G; Leo E; Pilotti S; Pierotti MA
Ann N Y Acad Sci; 2006 Sep; 1075():185-90. PubMed ID: 17108210
[TBL] [Abstract][Full Text] [Related]
40. [Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer].
Uehara M; Manaka D; Baba S; Oji Y; Hirata K; Shimizu M; Noguchi M
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1413-7. PubMed ID: 17876139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
